UC Irvine Breast Cancer Clinical Trials — Orange County, CA
Nov 26, 2025 · The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic …
Health Rounds: Pfizer drug delays progression of advanced breast cancer ...
4 days ago · Pfizer’s Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment ...
Adding tucatinib to first-line maintenance therapy delays disease ...
6 days ago · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
Orange County, CA - UCI Health
Oct 17, 2024 · Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with …
TUKYSA Added to First-Line Maintenance Therapy Extends Median ...
6 days ago · TUKYSA is approved in combination with trastuzumab and capecitabine to treat adults with HER2-positive advanced unresectable or metastatic breast cancer, including patients with brain …
Talzenna For Metastatic Breast Cancer: A Promising Treatment Option At Uci
Treating metastatic breast cancer can be difficult, as it often requires a combination of therapies and ongoing adjustments to treatment plans. Talzenna has been approved for use in patients with HER2 …
Adding Tucatinib to First-line Maintenance Therapy Delayed Disease ...
Dec 10, 2025 · Based on this, the U.S. Food and Drug Administration approved this drug in 2020 for treatment of unresectable locally advanced or metastatic HER2-positive breast cancer, including …
FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2 ...
1 day ago · The FDA has approved Enhertu (fam-trastuzumab deruxtecan-nxki; AstraZeneca and Daiichi Sankyo) plus Perjeta (pertuzumab) for the first-line treatment of adults with unresectable or …
UCI 22-222: A Phase III, Mutlicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant versus Alpelisib Plus Fulvestrant in Patients with Hormone Receptor …
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment …
1 day ago · The expanded approval for ENHERTU in the U.S. enables its use earlier as part of a combination regimen in the first-line setting of patients with HER2 positive metastatic breast cancer.